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Background: Sleep apnea is associated with worse outcomes following various kinds of surgeries. There
is a paucity of data on the association of sleep apnea with clinical outcomes after transcatheter aortic valve
replacement (TAVR).
Methods: We used National Inpatient Sample (NIS) data 2011–2014 to identify patients undergoing
TAVR. Association between sleep apnea and in-hospital postoperative outcomes were assessed by
multivariate logistic regression and 1:1 propensity score matching analyses.
Results: Of 42,189 patients who received TAVR, 4,605 patients (10.9%) had sleep apnea. Patients with
sleep apnea were more likely to be younger and male with higher prevalences of hypertension, diabetes
mellitus, dyslipidemia, chronic kidney disease, pulmonary hypertension and obesity who less frequently
received transapical access than those without sleep apnea. The group with sleep apnea had less bleeding
requiring transfusion (8.6% vs. 11.9%, P=0.01) than the counterpart. After adjusting for confounders,
the presence of sleep apnea was no longer independently associated with any of the studied outcomes
including all-cause mortality (OR 0.95; 95% CI: 0.64–1.42), stroke (OR 1.08; 95% CI: 0.65–1.81),
myocardial infarction (OR 0.66; 95% CI: 0.36–1.22), acute respiratory failure (OR 0.94; 95% CI: 0.72–1.23),
pneumothorax (OR 0.64; 95% CI: 0.26–1.59), vascular complication (OR 0.91; 95% CI: 0.69–1.22), bleeding
requiring transfusion (OR 0.85; 95% CI: 0.65-1.11), acute kidney injury requiring hemodialysis (OR 0.94;
95% CI: 0.53–1.66) and permanent pacemaker implantation (OR 1.12; 95% CI: 0.87–1.43). The length and
cost of hospital stay were not affected by sleep apnea, either.
Conclusions: With a prevalence of 10.9%, the presence of sleep apnea was not independently associated
with postoperative in-hospital outcomes in patients undergoing TAVR in NIS data 2011 to 2014.
Keywords: Sleep apnea; transcatheter aortic valve replacement (TAVR); in-hospital outcomes
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Introduction
Surgical aortic valve replacement and transcatheter aortic
valve replacement (TAVR) are the only effective therapy for
adult patients with symptomatic severe aortic stenosis to
offer survival benefit and symptom relief (1). For patients
with symptomatic severe aortic stenosis who are at high
or prohibitive risk for surgical aortic valve replacement,
TAVR is recommended as an alternative treatment based
on the evidence from PARTNER (Placement of Aortic
Transcatheter Valves) trial (1-7).
Sleep apnea has been shown to be associated with a wide
range of cardiopulmonary diseases as well as increased
postoperative complications (8-11). Approximately 25% of
adult patients presenting for elective surgery might have
sleep apnea (12). Accordingly, the American Society of
Anesthesiologists recommends preoperative evaluation of
obstructive sleep apnea and subsequent sleep study with
treatment if necessary (13).
Given the rising prevalence of sleep apnea (14) and
rapidly evolving TAVR with its exponentially increasing
utilization (15), it is imperative to examine the impact of
sleep apnea on postoperative outcomes of TAVR which may
have implications for cost-effective preoperative screening
and perioperative management of sleep apnea.
Methods
Data source and study population
Data were obtained from the Agency for Healthcare
Research and Quality Healthcare Cost and Utilization
Project, National Inpatient Sample (NIS) files between
2011 and 2014. NIS is the largest publicly available allpayer inpatient care data in the United States that allows
national estimates of hospitalization in a given year. Deidentified information for 146,032,189 discharges was
contained in NIS during the study period. Institutional
Review Board approval and informed consent were
not required for this study given the administrative
de-identified nature of the database. On the basis of
International Classification of Diseases-9th edition-Clinical
Modification (ICD-9-CM) codes, each patient data in the
NIS has ≤25 diagnoses including one principal diagnosis as
well as ≤15 procedures including one principal procedure
performed during the same hospitalization. Individual
patient’s data in NIS also includes Clinical Classification
Software (CCS) codes which groups multiple ICD-9-CM
codes into a lesser number of diagnoses and procedures
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categories to facilitate statistical analyses. We identified
study population, patient comorbidities and procedures
performed using a combination of ICD-9-CM and CCS
codes. Patients (aged ≥18 years) who underwent TAVR
from 2011 through 2014 were identified using ICD-9-CM
procedure codes of 35.05 and 35.06 recorded in any of the
15 procedures fields. Patients with data missing mortality
were excluded.
Study variables
NIS variables were used to examine patient’s age, gender,
race, household income quartiles, primary payer, length
of stay, in-hospital death and discharge location as
well as hospital’s region, location and teaching status.
Race was dichotomized into white and nonwhite. The
severity of comorbidities was defined by using the Deyo
modification of the Charlson Comorbidity Index where
higher scores indicate greater burden of comorbidities.
Sleep apnea was identified with ICD-9-CM codes of
327.20, 327.21, 327.23, 327.24, 327.26, 327.27, 780.51,
780.53, 780.57 and 786.03. Similar methodology has been
previously used to identify patients with sleep apnea (16).
Noninvasive ventilator use was captured using ICD-9CM codes of 93.90 and 93.91 (17). As a postoperative inhospital outcome measure, primary endpoint was defined
as experiencing any complication of all-cause death, stroke
(ICD 9 codes 997.00, 997.01, 997.02 and CCS code 109)
and acute myocardial infarction (CCS code 100). Secondary
endpoint was defined as the occurrence of one or more
postoperative complications of acute respiratory failure
(ICD 9 codes 518.81, 518.84, 799.1), pneumothorax (ICD
9 code 512.1), vascular complications (ICD 9 codes 900904, 447, 868.04, 868.14, 998.2, 999.2, 997.7, e870.x, 39.31,
39.41, 39.49, 39.52, 39.53, 39.56, 39.57, 39.58, 39.59,
39.79), hemorrhage requiring transfusion (ICD 9 codes
998.11, 998.12, 285.1 combined with 99.0x), acute kidney
injury requiring hemodialysis (ICD 9 codes 584.5, 584.6,
584.7, 584.8, 584.9 combined with 39.95 without principal
diagnosis of end stage renal disease; 585.6) or permanent
pacemaker implantation (ICD-9 codes 37.80, 37.81, 37.82,
37.83). Length of hospital stay was dichotomized at the 75th
percentile of stay days whereby prolonged length of stay
was defined as hospital stay exceeding the 75th percentile
(16,18). Data for race, household income quartile and
primary payer were missing in 7%, 1.5% and 0.2% of the
study population, respectively while data for the rest of
variables were available in 100% of patients.
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Statistical analysis
For all analyses, we followed the recommendations from
the Agency for Healthcare Research and Quality by
using survey specific statements (e.g., SURVEYFREQ,
SURVEYMEANS). Patient-specific and hospital-specific
discharge weights were used for inference of national
estimates. For subpopulation analyses, we used a domain
analysis for accurate variance calculations. All analyses
accounted for hospital level clustering of patients and
the sampling design using CLUSTER and STRATA
statements, respectively.
For descriptive analyses, we compared baseline patient
and hospital characteristics between cohorts with and
without sleep apnea. Continuous variables are presented
as means or medians; categorical variables are showed as
frequencies. For comparison of baseline characteristics,
either survey specific linear regression or Mann-Whitney U
test was used for continuous variables and Rao-Scott χ2 test
was used for categorical variables.
To assess the association between sleep apnea and
postoperative outcomes, multivariate logistic regression
models were created for each outcome by forcing sleep
apnea into a stepwise model selection procedure with
candidate comorbidity variables using entry and stay
criteria of a P value less than 0.25 and 0.1, respectively (19).
Candidate variables were included in the model if the
variable was significantly associated with outcome (P<0.25)
in the univariate logistic model, which were from among
age, gender, race, transapical access, smoking, hypertension,
diabetes mellitus, dyslipidemia, coronary artery disease,
previous PCI, previous CABG, pulmonary hypertension,
congestive heart failure, malignancy, peripheral vascular
disease, chronic kidney disease, chronic pulmonary disease,
anemia, coagulopathy, previous stroke, fluid/electrolyte
disorder, obesity, weight loss, Charlson/Deyo comorbidity
index, primary payer, household income quartile, hospital
region, hospital bed size and hospital location/teaching status.
Use of noninvasive ventilation (NIV) is likely to be either a
mediator on a causal pathway, if adjusted for, which would
falsely obscure possible association between sleep apnea and
postoperative outcomes or a collider, if controlled for, which
would falsely create spurious association leading to a bias.
Hence, we did not include the NIV in the main regression
analyses for adjustment. We used a dummy variable
adjustment method for missing data for race variable in order
to preserve the full sample size (20). Multicollinearity was
examined with VIF statement and all the possible two-way
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interactions were thoroughly tested. Regression model fit was
assessed by area under the receiver operator characteristic
curves and Hosmer-Lemeshow χ2 statistic.
Sensitivity analysis was performed using propensity score
method to examine the sensitivity of the primary results to
different statistical approaches. To determine each patient’s
propensity score of having sleep apnea, a non-parsimonious
multivariate logistic regression model (c statistic =0.75) was
used including all covariates used in the primary analysis.
The propensity score was incorporated as an additional
covariate in the primary multivariate logistic regression
model to create Model 2. Furthermore, we performed 1:1
matching between cohorts with and without sleep apnea
based on propensity score with a caliper width of 0.2 of
the standard deviation of the logit of the propensity score
using greedy algorithm (21). Standardized differences for
all covariates before and after matching were computed to
assess the accomplishment of matching where a standardized
difference of <10% for each covariate after matching is
suggestive of a successful matching (22). For matched group
outcome comparisons, conditional logistic regression was
used with exact test where appropriate. All tests were twosided with P values <0.05 indicating statistical significance.
SAS statistical software, version 9.4 (SAS institute, Cary,
NC, USA) was used for all statistical analyses.
Results
Baseline patient characteristics
Of 42,189 TAVR patients, 4,605 (10.9%) had sleep apnea
and those with obstructive sleep apnea accounted for 85.5%
of the entire sleep apnea cohort. Prevalence of sleep apnea
was higher in men than women (Figure 1). Patients with
sleep apnea were younger, more likely to be male and had
higher proportions of hypertension, diabetes, dyslipidemia,
pulmonary hypertension, chronic pulmonary disease and
obesity with greater Charlson/Deyo comorbidity index
score who received transapical access less frequently than
those without sleep apnea (Table 1). NIV was more often
used in patients with than those without sleep apnea (9.3%
vs. 2.5%, P<0.0001).
Postoperative outcomes stratified by sleep apnea
Figure 2 demonstrates observed in-hospital outcomes between
cohorts with and without sleep apnea. Sleep apnea patients had
lower incidences of primary endpoint, secondary endpoint,
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Figure 1 Prevalence of sleep apnea by gender among transcatheter
aortic valve replacement (TAVR) patients.

and bleeding requiring transfusion than the counterpart.
Association between sleep apnea and postoperative outcomes
Table S1 presents the unadjusted and adjusted association
between sleep apnea and in-hospital outcomes following
TAVR. After controlling for covariates, a presence of sleep
apnea was no longer statistically significantly associated
with any of the examined in-hospital outcomes (Model 1).
Multivariate logistic regression adjusting for an additional
variable of propensity score showed grossly consistent
results (Model 2). Propensity score matching analyses
following successful matching (Figure 3) resulted in the
similar findings (Model 3). Sleep apnea was independently
associated with neither prolonged hospital stay nor
discharge disposition. Controlling for the use of NIV
rendered consistent results (data not shown). Subgroup
analyses confined to obstructive sleep apnea showed grossly
consistent findings with the main analyses except for a lower
likelihood of discharge to home (Table S1).
Discussion
The main findings of our study are as follows: First, the
prevalence of sleep apnea in patients undergoing TAVR
was 10.9%. Second, sleep apnea was not independently
associated with worse postoperative outcomes following
TAVR. Third, perioperative provision of NIV in patients
with sleep apnea was 9.3%.
The prevalence of sleep apnea in TAVR patients is
similar to the national estimates in the United States (men:
12.8% vs. 14%, women: 8.9% vs. 5%) that has increased
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over the past two decades in parallel with rising level of
obesity which is the strongest risk factor for sleep apnea
(14,23-26). Gender gap of sleep apnea prevalence although
still significant was smaller in our study than previous
studies that reported the ratio of men to women with sleep
apnea to be 2–3 to 1. It is noteworthy that sleep apnea is
more prevalent in patients undergoing TAVR than those
receiving orthopedic, spinal, general or vascular surgeries
based on analyses of national data (16,27,28). Our findings
compare to the known association between sleep apnea and
multiple comorbidities including hypertension, diabetes
mellitus, dyslipidemia, chronic kidney disease, pulmonary
hypertension and obesity (26,29-33).
Patients with sleep apnea undergoing surgery may be
at increased risk for postoperative complications since
anesthesia or analgesia could cause pharyngeal relaxation
leading to exacerbation of apnea. A growing body of
literature suggests the potential link between sleep apnea
and worse postoperative outcomes following cardiac as
well as non-cardiac surgeries (9-11,16,27,34). Memtsoudis
et al. found a significant independent association between
sleep apnea and cardiopulmonary complications after
both orthopedic and general surgeries (16,27). Kaw et al.
reported an increased risk for postoperative complications
in patients with sleep apnea undergoing open heart
surgeries (9). Our findings focused on patients undergoing
TAVR are in contrast to the aforementioned results from
other surgeries. The observed incidences of primary
endpoint and secondary endpoint including bleeding were
lower, despite their higher burden of comorbidities, in
patients with than those without sleep apnea. There are
several plausible explanations for these observations. We
speculate higher postoperative complication rates in patients
without sleep apnea may have been partly contributed by
greater utilization of transapical access for TAVR than the
counterpart. In numerous studies, transapical access for
TAVR was found to be associated with worse outcomes
compared with transfemoral access (35-37). In addition,
the higher proportion of women in the group without
sleep apnea may explain the higher bleeding complications
as female gender has been shown to be a predictor of
bleeding complications after TAVR in previous studies
(38-42). However, after adjusting for all potential
confounding factors available in the study, the presence of
sleep apnea no longer remained statistically significantly
associated with any of the examined in-hospital
postoperative outcomes of TAVR. This finding suggests
that observed differences in postoperative outcomes
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Table 1 Baseline characteristics of patients with and without sleep apnea
Baseline characteristics

Overall

Without sleep apnea

Sleep apnea

Number of patients, (%)

42,189

37,584 (89.1%)

Age (years), mean ± SE

81.1±0.1

81.7±0.1

76.9±0.3

18–49

250 (0.6%)

216 (0.6%)

35 (0.8%)

50–64

1,882 (4.5%)

1,487 (4.0%)

394 (8.6%)

65–79

11,750 (27.9%)

9,577 (25.5%)

2,173 (47.2%)

80–

28,308 (67.1%)

26,305 (70.0%)

2,003 (43.5%)

Women

20,074 (47.6%)

18,296 (48.7%)

1,778 (38.6%)

4,605 (10.9%)

Age group (years)

<0.0001
<0.0001

Race
White

P value

<0.0001
0.41

34,229 (87.2%)

30,469 (87.1%)

3,760 (88.0%)

5,025 (12.8%)

4,513 (12.9%)

511 (12.0%)

1,286 (3.0%)

1,166 (3.1%)

120 (2.6%)

Hypertension

34,375 (81.5%)

30,503 (81.2%)

3,872 (84.1%)

0.02

Diabetes mellitus

14,136 (33.5%)

11,832 (31.5%)

2,304 (50.0%)

<0.0001

Dyslipidemia

27,144 (64.3%)

23,992 (63.8%)

3,152 (68.4%)

0.01

Chronic kidney disease

15,868 (37.6%)

13,945 (37.1%)

1,923 (41.8%)

0.01

Pulmonary hypertension

9,446 (22.4%)

8,155 (21.7%)

1,291 (28.0%)

<0.0001

Congestive heart failure

31,196 (73.9%)

27,758 (73.9%)

3,438 (74.7%)

0.61

Peripheral vascular disease

10,141 (24.0%)

8,943 (23.8%)

1,198 (26.0%)

0.13

Coronary artery disease

30,109 (71.4%)

26,802 (71.3%)

3,307 (71.8%)

0.75

Previous PCI

7,903 (18.7%)

7,024 (18.7%)

879 (19.1%)

0.77

Previous CABG

9,388 (22.2%)

8,362 (22.2%)

1,026 (22.3%)

0.98

Chronic pulmonary disease

11,573 (27.4%)

9,786 (26.0%)

1,787 (38.8%)

<0.0001

Anemia

11,158 (26.4%)

9,981 (26.6%)

1,177 (25.6%)

0.51

Coagulopathy

10,059 (23.8%)

9018 (24.0%)

1,041 (22.6%)

0.31

History of stroke

4,280 (10.1%)

3,838 (10.2%)

442 (9.6%)

0.55

Malignancy

6,297 (14.9%)

5,688 (15.1%)

608 (13.2%)

0.11

11,273 (26.7%)

10,140 (27.0%)

1,132 (24.6%)

0.17

Obesity

5,919 (14.0%)

4,027 (10.7%)

1,893 (41.1%)

<0.0001

Weight loss

2,165 (5.1%)

2,030 (5.4%)

134 (2.9%)

0.003

Nonwhite
Smoking history

Fluid and electrolyte disorder

Charlson/Deyo comorbidity index, median (IQR)

2.3 (1.1–3.6)

0.41

2.3 (1.0–3.6)

2.7 (1.5–4.0)

<0.0001

Noninvasive ventilation

1,378 (3.3%)

949 (2.5%)

429 (9.3%)

<0.0001

Transapical access

8,523 (20.2%)

7,746 (20.6%)

777 (16.9%)

0.01

1st quartile

8,617 (20.8%)

7,893 (21.4%)

724 (16.0%)

2nd quartile

10,300 (24.8%)

8,976 (24.3%)

1,324 (29.3%)

3rd quartile

10,660 (25.7%)

9,342 (25.3%)

1,318 (29.1%)

4th quartile

11,890 (28.7%)

10,731 (29.0%)

1,159 (25.6%)

Mean household income

<0.0001

Table 1 (continued)
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Table 1 (continued)
Baseline characteristics

Overall

Without sleep apnea

Sleep apnea

Primary payer

P value
0.004

Medicare/medicaid

38,415 (91.2%)

34,364 (91.6%)

4,051 (88.2%)

2,960 (7.0%)

2,517 (6.7%)

444 (9.7%)

750 (1.8%)

650 (1.7%)

100 (2.2%)

Private including HMO
Self-pay/no charge/other
Hospital region

0.001

Northeast

10,867 (25.8%)

9,909 (26.4%)

958 (20.8%)

9,314 (22.1%)

8,086 (21.5%)

1,228 (26.7%)

South

14,447 (34.2%)

12,809 (34.1%)

1,638 (35.6%)

West

7,561 (17.9%)

6,781 (18.0%)

781 (16.9%)

Midwest or North Central

Hospital bed size

0.12

Small

1,995 (4.7%)

1,815 (4.8%)

180 (3.9%)

Medium

6,787 (16.1%)

5,966 (15.9%)

821 (17.8%)

33,408 (79.2%)

29,803 (79.3%)

3,604 (78.3%)

Large
Hospital location/teaching status

0.30

Rural

305 (0.7%)

260 (0.7%)

45 (1.0%)

4,312 (10.2%)

3,893 (10.4%)

420 (9.1%)

37,572 (89.1%)

33,431 (89.0%)

4,141 (89.9%)

57,901±648 [51,295]

58,109±661 [51,341]

Urban non-teaching
Urban teaching
Cost of hospitalization ($), mean ± SE [median]
Length of stay, mean ± SE (median)

8.1±0.1 (5.4)

8.1±0.1 (5.5)

56,200±1,211 [50,869]
7.5±0.2 (5.4)

0.36
0.10

PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; HMO, health maintenance organization.

35

P=0.04

30
25
20
(%)

15
10

P=0.01
P=0.048

P=0.2
P=0.13

5
0

P=0.3

P=0.61

P=0.3

P=0.11

P=0.86

P=0.07

Primary
endpoint

Death

Stroke

MI

Secondary
endpoint

ARF

Pneumoth
orax

Vasc Cx

Bleeding

AKI

Without sleep apnea

8.4

4.3

2.8

2.2

32.4

8.4

1.2

6.9

11.9

1.7

9.9

Sleep apnea

6.5

3.3

2.2

1.4

29.2

7.9

0.5

5.9

8.6

1.6

11.1

PPM

Figure 2 In-hospital outcomes after transcatheter aortic valve replacement (TAVR) in patients with and without sleep apnea.

between patients with and without sleep apnea were driven
by confounders. It is reassuring that in-hospital outcomes
are comparable in patients undergoing TAVR regardless of
the presence of sleep apnea after adjusting for confounders.

© Annals of Translational Medicine. All rights reserved.

Guidelines from the American Society of Anesthesiologists
recommend that patients with sleep apnea on preoperative
NIV continue the therapy after surgery (13). Previous studies
demonstrated the low frequency of provision of CPAP in
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Obesity
Age
Diabetes mellitus
Chronic pulmonary disease
Charlson/Deyo comorbidity Index
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Pulmonary hypertension
Weight loss
Transapical access
Chronic kidney disease
Dyslipidemia
Hypertension
Malignancy
Fluid/electrolyte disorder
Peripheral vascular disease
Coagulopathy
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Congestive heart failure
Previous stroke
Coronary artery disease
Previous PCI
Previous CABG

Before Propensity Score Matching
After Propensity Score Matching

0
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80

Standardized Difference

Figure 3 Standardized differences between transcatheter aortic valve replacement (TAVR) patients with and without sleep apnea.

the hospital setting (17,43). In our study, utilization of NIV
for patients with sleep apnea was only 9.3% although higher
than patients without sleep apnea. The lower rate of NIV
use would suggest possible room for quality improvement
in perioperative management for patients with sleep apnea
undergoing TAVR despite currently lacking evidence of the
benefit of NIV use on postoperative outcomes.
This is the first study, of which we are aware, that
examined the association between sleep apnea and inhospital outcomes after TAVR with a large population.
This study is based on a large real-world data which confers
generalizability of the findings. Also, use of different
statistical methodologies for the analyses would consolidate
the internal validity of our study.
Several important factors need to be noted when
interpreting the result of our study. First, the logistic
EuroScore and Society of Thoracic Surgeons score were not
available in NIS data for adjustment although multivariate
regression and propensity score matching achieved
adequate balance including Charlson/Deyo index between
the two study cohorts. Second, data on types of anesthesia
used for TAVR was not available. General anesthesia could
potentially interact with sleep apnea on postoperative
outcomes although the outcomes of both general
anesthesia and local anesthesia were comparable after
© Annals of Translational Medicine. All rights reserved.

TAVR (44) that would preclude the type of anesthesia from
biasing the association as a confounder. Third, potential
misclassification of sleep apnea should be considered given a
large proportion of sleep apnea remains undiagnosed when
patients present to surgery. Preexisting undiagnosed sleep
apnea was prevalent in more than 80% of surgical patients
(12,45). This potential non-differential misclassification
of sleep apnea could have biased the possible association
between sleep apnea and postoperative outcomes toward
the null. Nevertheless, the absence of the independent
association between sleep apnea and TAVR outcomes in
our study is still convincing given that previous studies with
the even lower prevalence of sleep apnea still demonstrated
worse outcomes after other surgeries in patients with sleep
apnea (16,27). Fourth, no detailed clinical information such
as post-TAVR aortic regurgitation, site of bleeding and
postoperative hemodynamic performance of the valve were
available for study. Fifth, the severity of sleep apnea was not
accounted for in the absence of information on the apneahypopnea index in NIS data.
Conclusions
In patients undergoing TAVR for the treatment of
symptomatic severe aortic stenosis, the prevalence of sleep
apnea was 10.9%, and the presence of sleep apnea was not
atm.amegroups.com
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independently associated with postoperative in-hospital
outcomes in the NIS data of the years from 2011 to 2014.
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Supplementary
Table S1 Association between sleep apnea and in-hospital outcomes following TAVR (non-sleep apnea cohort as reference)
Unadjusted OR (95% CI)

P value

Adjusted OR
(95% CI); Model 1

P value

Adjusted OR
(95% CI); Model 2

P value

Adjusted OR (95% CI);
Model 3

P value

Unadjusted OR
(95% CI)

P value

Adjusted OR
(95% CI)

P value

0.76 (0.58–0.99)

0.049

0.93 (0.69–1.25)

0.61

1.03 (0.76–1.39)

0.85

1.06 (0.72–1.55)

0.77

0.74 (0.56–0.99)

0.045

0.90 (0.65–1.24)

0.51

All-cause mortality

0.75 (0.52–1.09)

0.13

0.95 (0.64–1.42)

0.81

0.98 (0.66–1.46)

0.93

0.97 (0.57–1.62)

0.89

0.73 (0.49–1.10)

0.13

0.92 (0.60–1.41)

0.69

Stroke

0.78 (0.49–1.25)

0.30

1.08 (0.65–1.81)

0.77

1.13 (0.67–1.93)

0.64

1.25 (0.65–2.41)

0.51

0.83 (0.51–1.35)

0.46

1.16 (0.67–2.00)

0.60

Myocardial infarction

0.64 (0.37–1.11)

0.11

0.66 (0.36–1.22)

0.18

0.77 (0.41–1.43)

0.41

0.81 (0.39–1.69)

0.58

0.52 (0.27–1.01)

0.05

0.52 (0.25–1.09)

0.09

0.86 (0.75–0.99)

0.04

0.92 (0.79–1.07)

0.28

0.93 (0.79–1.09)

0.35

0.98 (0.80–1.20)

0.83

0.93 (0.80–1.07)

0.31

0.99 (0.84–1.16)

0.87

Acute respiratory failure

0.94 (0.73–1.20)

0.61

0.94 (0.72–1.23)

0.65

0.92 (0.69–1.22)

0.56

1.20 (0.84–1.72)

0.32

0.95 (0.73–1.23)

0.69

0.94 (0.71–1.24)

0.66

Pneumothorax

0.45 (0.18–1.09)

0.08

0.64 (0.26–1.59)

0.33

0.65 (0.25–1.65)

0.36

0.46 (0.12–1.42)

0.21

0.53 (0.22–1.30)

0.16

0.78 (0.31–1.93)

0.59

Vascular complication

0.83 (0.63–1.10)

0.20

0.91 (0.69–1.22)

0.54

0.94 (0.70–1.26)

0.68

0.71 (0.49–1.02)

0.06

0.88 (0.65–1.18)

0.38

0.97 (0.71–1.31)

0.82

Bleeding requiring transfusion

0.70 (0.55–0.90)

0.01

0.85 (0.65–1.11)

0.22

0.86 (0.65–1.12)

0.26

0.84 (0.61–1.15)

0.26

0.73 (0.56–0.94)

0.01

0.87 (0.66–1.16)

0.34

Acute kidney injury requiring
hemodialysis

0.95 (0.56–1.64)

0.86

0.94 (0.53–1.66)

0.82

0.99 (0.57–1.71)

0.96

0.83 (0.42–1.65)

0.60

1.05 (0.60–1.85)

0.86

1.00 (0.54–1.83)

0.99

Permanent pacemaker implantation

1.13 (0.90–1.42)

0.30

1.12 (0.87–1.43)

0.39

1.11 (0.86–1.44)

0.41

1.25 (0.92–1.71)

0.16

1.22 (0.97–1.54)

0.09

1.21 (0.94–1.55)

0.14

Prolonged length of stay
(length of stay ≥9 days)

0.89 (0.75–1.05)

0.15

0.98 (0.82–1.17)

0.78

0.98 (0.81–1.17)

0.80

0.96 (0.78–1.19)

0.71

1.01 (0.86–1.20)

0.88

1.11 (0.92–1.34)

0.28

Discharge to home

1.16 (1.01–1.34)

0.04

0.87 (0.74–1.03)

0.11

0.88 (0.74–1.04)

0.13

1.00 (0.82–1.23)

1.00

1.09 (0.94–1.27)

0.24

0.83 (0.69–0.98)

0.03

In-hospital outcomes
Primary endpoints

Secondary endpoints

Model 1 was adjusted for candidate covariates that had significant univariate association with outcomes (P<0.25) from among age, gender, trans–apical approach, white race, smoking, hypertension, diabetes mellitus, dyslipidemia, previous percutaneous
coronary intervention, previous coronary artery bypass grafting, pulmonary hypertension, congestive heart failure, malignancy, peripheral vascular disease, chronic kidney disease, chronic pulmonary disease, Charlson/Deyo comorbidity scores, anemia,
coagulopathy, previous stroke, fluid/electrolytes disorder, obesity, weight loss, primary payer, income quartile, hospital region, hospital bed size and hospital location/teaching status. Mode 2 was adjusted for propensity score in addition to the same
covariates from Model 1. Model 3 was adjusted for covariates by using 1:1 propensity score matching. C-statistics of multivariate regression Model 1 for primary endpoints, mortality, stroke, myocardial infarction, secondary endpoints, acute respiratory
failure, pneumothorax, vascular complication, bleeding, acute kidney injury and permanent pacemaker implantation were 0.73, 0.73, 0.82, 0.75, 0.63, 0.73, 0.70, 0.61, 0.67, 0.88 and 0.60, respectively. All P values of Hosmer-Lemeshow goodness of fit test for
each outcome were >0.05. There was no multicollinearity detected (all tolerance >0.4) and no two way interaction with sleep apnea was found for each outcome. TAVR, transcatheter aortic valve replacement.

